In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis.

scientific article published on 17 April 2017

In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/AAC.02479-16
P8608Fatcat IDrelease_g6impbrmd5ekpgy3fxwe5qyrku
P953full work available at URLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444178
P932PMC publication ID5444178
P698PubMed publication ID28416540

P50authorSeyedmojtaba SeyedmousaviQ40062294
Willem MelchersQ56859383
Paul E. VerweijQ70514014
P2093author name stringJohan W Mouton
P2860cites workAzole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?Q28082352
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosisQ28217179
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of AmericaQ28263689
Microbial Pathogens in the Fungal KingdomQ28740823
Triazole Resistance in Aspergillus Species: An Emerging ProblemQ30235566
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanismQ30853962
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.Q33613758
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of AmericaQ34532546
Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapyQ34754956
Aspergillosis. Pathogenesis, clinical manifestations, and therapyQ35038459
Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.Q35076830
Systemic mycoses in the immunocompromised host: an update in antifungal therapyQ35093104
Review of newer antifungal and immunomodulatory strategies for invasive aspergillosisQ35219726
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelQ35385554
Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009.Q35848799
Underlying disorders and their impact on the host response to infectionQ36291747
Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directionsQ36521174
Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosisQ36757621
When primary antifungal therapy failsQ37141191
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/Q37164067
Epidemiology and Molecular Characterizations of Azole Resistance in Clinical and Environmental Aspergillus fumigatus Isolates from China.Q37287782
Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi.Q37865279
Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.Q38140015
Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.Q38195132
The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.Q38234496
Systemic Antifungal Agents: Current Status and Projected Future Developments.Q38796140
Occurrence of triazole-resistant Aspergillus fumigatus with TR34/L98H mutations in outdoor and hospital environment in KuwaitQ38863185
Changes in the epidemiological landscape of invasive mould infections and diseaseQ38868919
Therapeutic outcome in invasive aspergillosisQ38970340
Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany.Q40274784
First description of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in France.Q41280441
Multi-triazole-resistant Aspergillus fumigatus infections in AustraliaQ41321727
Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus.Q41542809
First Detection of TR34 L98H and TR46 Y121F T289A Cyp51 Mutations in Aspergillus fumigatus Isolates in the United StatesQ41842226
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasisQ42112304
Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania.Q42206937
First reported case of azole-resistant aspergillus fumigatus due to the TR/L98H mutation in GermanyQ42383280
SCH56592 treatment of murine invasive aspergillosisQ42538220
Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failureQ42555868
Multiple Fungicide-Driven Alterations in Azole-Resistant Aspergillus fumigatus, Colombia, 2015.Q42922120
Azole-resistant Aspergillus fumigatus, Iran.Q43171569
Azole resistance in Aspergillus: a growing public health menaceQ43607400
Multidrug resistance in Aspergillus fumigatus.Q44261807
Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery.Q44318186
EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazoleQ45152541
Azole-resistant central nervous system aspergillosis.Q46094844
Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemiaQ46487039
Voriconazole-Susceptible and Voriconazole-Resistant Aspergillus fumigatus Coinfection.Q53789869
Aspergillosis—and a misleading sensitivity resultQ63914856
Invasive aspergillosis in critically ill patients without malignancyQ80269940
Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasisQ82740226
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectAspergillus fumigatusQ134359
aspergillosisQ259626
amphotericin BQ412223
immunosuppressionQ1455316
P577publication date2017-05-24
P1433published inAntimicrobial Agents and ChemotherapyQ578004
P1476titleIn Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis
P478volume61

Reverse relations

cites work (P2860)
Q92953659In Vitro and In Vivo Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus
Q55511181Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Search more.